Part of the benefit may be due to BP-lowering effects of the drug and/or fewer abnormal heart rhythms, says Seemant ...

Three trials showed no improvement in functional outcomes, and the potential for harm, versus medical therapy alone.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Female patients who deliver twins vs singletons are more apt to return to the hospital for CVD, especially during the first ...

The Medicare data contradict results from the TCW randomized trial but better represent real-world practice, say authors.

Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.

This small but meaningful change seen in California may add up to a generational impact on consumption, but only time will ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

With growth in percutaneous fixes for the valve, surgeons at STS 2025 called for innovation, team-based care, and more data.

Due to uncertainty within the data, the impact of looser driving restrictions still merits close scrutiny, a researcher says.

An analysis of the PURE study shows some gains but “little to no improvement in most places over time,” says Philip Joseph.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.